FierceBiotech

AbbVie crowns Gilgamesh its next M&A target with $1B buyout talks: report

AbbVie has reportedly added Gilgamesh Pharmaceuticals to its shopping list. The Big Pharma teamed up with Gilgamesh last year and, according to Bloomberg, is now in talks about buying the mental ...
FierceBiotech

AbbVie inks $2B-plus next-gen neuro deal with Gilgamesh

AbbVie has inked a new deal with Gilgamesh Pharmaceuticals aimed at developing next-gen therapies for psychiatric disorders. The two companies have agreed to research and develop a portfolio of ...
STAT

AbbVie to buy Gilgamesh’s psychedelic drug for up to $1.2 billion

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. AbbVie on Monday said it ...
GEN

AbbVie Embraces Psychedelic Drug with Up-to-$1.2B Deal for Gilgamesh’s MDD Candidate

AbbVie has agreed to acquire Gilgamesh Pharmaceuticals’ lead pipeline asset bretisilocin, a clinical-stage candidate designed to treat moderate-to-severe major depressive disorder (MDD), for up to ...
Reuters

AbbVie in talks to acquire Gilgamesh Pharmaceuticals, Bloomberg News reports

July 30 (Reuters) - Drugmaker AbbVie (ABBV.N), opens new tab is in talks to acquire privately-held mental health therapeutics company Gilgamesh Pharmaceuticals in a deal worth about $1 billion, ...